BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 17912434)

  • 1. Combined effect of 2-5A-linked antisense against telomerase RNA and conventional therapies on human malignant glioma cells in vitro and in vivo.
    Iwado E; Daido S; Kondo Y; Kondo S
    Int J Oncol; 2007 Nov; 31(5):1087-95. PubMed ID: 17912434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination therapy of malignant glioma cells with 2-5A-antisense telomerase RNA and recombinant adenovirus p53.
    Komata T; Kondo Y; Koga S; Ko SC; Chung LW; Kondo S
    Gene Ther; 2000 Dec; 7(24):2071-9. PubMed ID: 11223987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination therapy of 2-5A antisense against telomerase RNA and cisplatin for malignant gliomas.
    Kondo Y; Komata T; Kondo S
    Int J Oncol; 2001 Jun; 18(6):1287-92. PubMed ID: 11351264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 2-5A antisense telomerase RNA therapy for intracranial malignant gliomas.
    Mukai S; Kondo Y; Koga S; Komata T; Barna BP; Kondo S
    Cancer Res; 2000 Aug; 60(16):4461-7. PubMed ID: 10969793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 2-5A antisense therapy directed against human telomerase RNA inhibits telomerase activity and induces apoptosis without telomere impairment in cervical cancer cells.
    Yatabe N; Kyo S; Kondo S; Kanaya T; Wang Z; Maida Y; Takakura M; Nakamura M; Tanaka M; Inoue M
    Cancer Gene Ther; 2002 Jul; 9(7):624-30. PubMed ID: 12082463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of prostate cancer in vitro and in vivo with 2-5A-anti-telomerase RNA component.
    Kondo Y; Koga S; Komata T; Kondo S
    Oncogene; 2000 Apr; 19(18):2205-11. PubMed ID: 10822370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Telomerase RNA inhibition using antisense oligonucleotide against human telomerase RNA linked to a 2',5'-oligoadenylate.
    Kondo Y; Kondo S
    Methods Mol Biol; 2007; 405():97-112. PubMed ID: 18369820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 2-5A antisense directed against telomerase RNA produces apoptosis in ovarian cancer cells.
    Kushner DM; Paranjape JM; Bandyopadhyay B; Cramer H; Leaman DW; Kennedy AW; Silverman RH; Cowell JK
    Gynecol Oncol; 2000 Feb; 76(2):183-92. PubMed ID: 10637068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of caspase transfer using the human telomerase reverse transcriptase promoter and conventional therapies for malignant glioma cells.
    Takeuchi H; Kanzawa T; Kondo Y; Komata T; Hirohata S; Kyo S; Kondo S
    Int J Oncol; 2004 Jul; 25(1):57-63. PubMed ID: 15201989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human telomerase RNA degradation by 2'-5'-linked oligoadenylate antisense chimeras in a cell-free system, cultured tumor cells, and murine xenograft models.
    Paranjape JM; Xu D; Kushner DM; Okicki J; Lindner DJ; Cramer H; Silverman RH; Leaman DW
    Oligonucleotides; 2006; 16(3):225-38. PubMed ID: 16978086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted therapy of human malignant glioma in a mouse model by 2-5A antisense directed against telomerase RNA.
    Kondo S; Kondo Y; Li G; Silverman RH; Cowell JK
    Oncogene; 1998 Jun; 16(25):3323-30. PubMed ID: 9681832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of bladder cancer cells in vitro and in vivo with 2-5A antisense telomerase RNA.
    Koga S; Kondo Y; Komata T; Kondo S
    Gene Ther; 2001 Apr; 8(8):654-8. PubMed ID: 11320413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of telomerase antisense oligonucleotides simultaneously targeting hTR and hTERT produces synergism of inhibition of telomerase activity and growth in human colon cancer cell line.
    Fu XH; Zhang JS; Zhang N; Zhang YD
    World J Gastroenterol; 2005 Feb; 11(6):785-90. PubMed ID: 15682468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Temozolomide enhances herpes simplex virus thymidine kinase/ganciclovir therapy of malignant glioma.
    Rainov NG; Fels C; Droege JW; Schäfer C; Kramm CM; Chou TC
    Cancer Gene Ther; 2001 Sep; 8(9):662-8. PubMed ID: 11593335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antisense telomerase RNA inhibits the growth of human glioma cells in vitro and in vivo.
    You Y; Pu P; Huang Q; Xia Z; Wang C; Wang G; Yu C; Yu JJ; Reed E; Li QQ
    Int J Oncol; 2006 May; 28(5):1225-32. PubMed ID: 16596239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of telomerase RNA (hTR) in cervical cancer by adenovirus-delivered siRNA.
    Li Y; Li H; Yao G; Li W; Wang F; Jiang Z; Li M
    Cancer Gene Ther; 2007 Aug; 14(8):748-55. PubMed ID: 17479103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thresholds of O6-alkylguanine-DNA alkyltransferase which confer significant resistance of human glial tumor xenografts to treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea or temozolomide.
    Kokkinakis DM; Bocangel DB; Schold SC; Moschel RC; Pegg AE
    Clin Cancer Res; 2001 Feb; 7(2):421-8. PubMed ID: 11234899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid blockade of telomerase activity and tumor cell growth by the DPL lipofection of ribbon antisense to hTR.
    Bajpai AK; Park JH; Moon IJ; Kang H; Lee YH; Doh KO; Suh SI; Chang BC; Park JG
    Oncogene; 2005 Sep; 24(43):6492-501. PubMed ID: 16170384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antisense telomerase induced cell growth inhibition, cell cycle arrest and telomerase activity down-regulation in gastric and colon cancer cells.
    Wong SC; Yu H; Moochhala SM; So JB
    Anticancer Res; 2003; 23(1A):465-9. PubMed ID: 12680250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Caspase-8 gene therapy using the human telomerase reverse transcriptase promoter for malignant glioma cells.
    Komata T; Kondo Y; Kanzawa T; Ito H; Hirohata S; Koga S; Sumiyoshi H; Takakura M; Inoue M; Barna BP; Germano IM; Kyo S; Kondo S
    Hum Gene Ther; 2002 Jun; 13(9):1015-25. PubMed ID: 12067435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.